207 related articles for article (PubMed ID: 28883511)
1. Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact.
Cohen M; Vistarop AG; Huaman F; Narbaitz M; Metrebian F; De Matteo E; Preciado MV; Chabay PA
Sci Rep; 2017 Sep; 7(1):10813. PubMed ID: 28883511
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr Virus-Positive Diffuse Large B cell Lymphoma in the Experience of a Tertiary Medical Center in Poland.
Ziarkiewicz M; Wołosz D; Dzieciątkowski T; Wilczek E; Dwilewicz-Trojaczek J; Jędrzejczak WW; Gierej B; Ziarkiewicz-Wróblewska B
Arch Immunol Ther Exp (Warsz); 2016 Apr; 64(2):159-69. PubMed ID: 26084760
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment.
Cohen M; De Matteo E; Narbaitz M; Carreño FA; Preciado MV; Chabay PA
Int J Cancer; 2013 Apr; 132(7):1572-80. PubMed ID: 22987474
[TBL] [Abstract][Full Text] [Related]
5. Reappraisal of Epstein-Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells.
Ohashi A; Kato S; Okamoto A; Inaguma Y; Satou A; Tsuzuki T; Emi N; Okamoto M; Nakamura S
Histopathology; 2017 Jul; 71(1):89-97. PubMed ID: 28231401
[TBL] [Abstract][Full Text] [Related]
6. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.
Keane C; Tobin J; Gunawardana J; Francis S; Gifford G; Gabrielli S; Gill A; Stevenson W; Talaulikar D; Gould C; Jain S; Birch S; Hertzberg M; Gandhi MK
Eur J Haematol; 2019 Sep; 103(3):200-207. PubMed ID: 31211907
[TBL] [Abstract][Full Text] [Related]
7. Presence of Epstein-Barr virus (EBV) antigens detected by sensitive methods has no influence on local immune environment in diffuse large B cell lymphoma.
Mangiaterra T; Alonso-Alonso R; Rabinovich A; De Dios Soler M; Galluzzo L; Soria M; Colli S; De Matteo E; Rodriguez Pinilla SM; Chabay P
Cancer Immunol Immunother; 2024 Jan; 73(2):29. PubMed ID: 38280007
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic Epstein-Barr virus-positive large B cell lymphoma: a regulatory B cell-derived neoplasia?
Tabanelli V; Santiago-Pacheco V; Corbellino M; Calleri A; Agostinelli C; Parravicini C; Pileri SA
Histopathology; 2017 Mar; 70(4):650-656. PubMed ID: 27782313
[TBL] [Abstract][Full Text] [Related]
9. Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases.
Elsayed AA; Satou A; Eladl AE; Kato S; Nakamura S; Asano N
Histopathology; 2017 Mar; 70(4):579-594. PubMed ID: 27735994
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time.
Chang ST; Lu YH; Lu CL; Weng SF; Lin SH; Kuo SY; Chuang YT; Takeuchi K; Ohshima K; Chuang SS
J Clin Pathol; 2014 Apr; 67(4):326-32. PubMed ID: 24218026
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-positive diffuse large B-cell lymphoma in children: a disease reminiscent of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
Uccini S; Al-Jadiry MF; Scarpino S; Ferraro D; Alsaadawi AR; Al-Darraji AF; Moleti ML; Testi AM; Al-Hadad SA; Ruco L
Hum Pathol; 2015 May; 46(5):716-24. PubMed ID: 25704629
[TBL] [Abstract][Full Text] [Related]
12. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.
Park S; Lee J; Ko YH; Han A; Jun HJ; Lee SC; Hwang IG; Park YH; Ahn JS; Jung CW; Kim K; Ahn YC; Kang WK; Park K; Kim WS
Blood; 2007 Aug; 110(3):972-8. PubMed ID: 17400912
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.
Ozsan N; Cagirgan S; Saydam G; Gunes A; Hekimgil M
Pathol Res Pract; 2013 Aug; 209(8):471-8. PubMed ID: 23726928
[TBL] [Abstract][Full Text] [Related]
14. [Prevalence and clinico-pathological characteristics in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma in a high complexity hospital in Cali, Columbia].
Amaya D; Moreno JC; Calvache N; Castro A; Pérez B; Silva N
Rev Esp Patol; 2019; 52(3):139-146. PubMed ID: 31213254
[TBL] [Abstract][Full Text] [Related]
15. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Morishima S; Nakamura S; Yamamoto K; Miyauchi H; Kagami Y; Kinoshita T; Onoda H; Yatabe Y; Ito M; Miyamura K; Nagai H; Moritani S; Sugiura I; Tsushita K; Mihara H; Ohbayashi K; Iba S; Emi N; Okamoto M; Iwata S; Kimura H; Kuzushima K; Morishima Y
Leuk Lymphoma; 2015 Apr; 56(4):1072-8. PubMed ID: 24975317
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era.
Sato A; Nakamura N; Kojima M; Ohmachi K; Carreras J; Kikuti YY; Numata H; Ohgiya D; Tazume K; Amaki J; Moriuchi M; Miyamoto M; Aoyama Y; Kawai H; Ichiki A; Hara R; Kawada H; Ogawa Y; Ando K
Cancer Sci; 2014 Sep; 105(9):1170-5. PubMed ID: 24974976
[TBL] [Abstract][Full Text] [Related]
17. Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma.
Witte HM; Merz H; Biersack H; Bernard V; Riecke A; Gebauer J; Lehnert H; von Bubnoff N; Feller AC; Gebauer N
Br J Haematol; 2020 Apr; 189(2):257-268. PubMed ID: 31958882
[TBL] [Abstract][Full Text] [Related]
18. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.
Zhao CX; Yan ZX; Wen JJ; Fu D; Xu PP; Wang L; Cheng S; Hu JD; Zhao WL
Mol Cancer; 2021 Dec; 20(1):153. PubMed ID: 34852843
[TBL] [Abstract][Full Text] [Related]
19. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Beltran BE; Quiñones P; Morales D; Malaga JM; Chavez JC; Sotomayor EM; Castillo JJ
Hematol Oncol; 2018 Feb; 36(1):93-97. PubMed ID: 28639256
[TBL] [Abstract][Full Text] [Related]
20. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
Quan L; Chen X; Liu A; Zhang Y; Guo X; Yan S; Liu Y
PLoS One; 2015; 10(9):e0136476. PubMed ID: 26361042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]